|
OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. |
|
|
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; MSD; Sandoz |
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/Tesaro; MSD |
Speakers' Bureau - AstraZeneca; GlaxoSmithKline/Tesaro; MSD |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline/Tesaro; MSD; Roche |
|
|
Honoraria - AstraZeneca/Merck; Daiichi Sankyo; Pierre Fabre; Roche; SERVIER |
|
|
|
|
Stock and Other Ownership Interests - eXYSTAT |
|
Consulting or Advisory Role - Abbvie; Biocodex; GenSight Biologics; Guerbet |
|
|
Honoraria - AstraZeneca; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
Consulting or Advisory Role - Clovis Oncology |
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; MSD; Roche |
|
|
Consulting or Advisory Role - AstraZeneca/Merck; Eisai; GlaxoSmithKline; MSD; PharmaMar; Roche |
Speakers' Bureau - AstraZeneca/Merck; GlaxoSmithKline; MSD; PharmaMar; Roche |
Travel, Accommodations, Expenses - Roche; Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline |
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
Honoraria - AstraZeneca/Merck; Clovis Oncology; GlaxoSmithKline |
Consulting or Advisory Role - AstraZeneca/Merck; Clovis Oncology; GlaxoSmithKline |
Research Funding - AstraZeneca/Merck; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; ImmunoGen; Novartis |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
Consulting or Advisory Role - AstraZeneca/Merck; BMSi; Gilead Sciences; MSD Oncology; Novartis; Sanofi |
Travel, Accommodations, Expenses - MSD Oncology; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck |
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Novartis; Novartis; Novocure; Shattuck Labs |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst) |
|
|
Employment - AstraZeneca Canada |
|
|
Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline; Lilly; MSD; Pfizer |
Travel, Accommodations, Expenses - MSD; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; clovis oncology; Roche; Tesaro/GSK; Tesaro/GSK |
|
|
Employment - Arcagy-Gineco |
Honoraria - AstraZeneca; GlaxoSmithKline |
Consulting or Advisory Role - AstraZeneca; Incyte; Merck; Roche |
Research Funding - AstraZeneca (Inst) |
Other Relationship - Arcagy-Gineco |